Astellas Mulls Potential Impact Of New US CRL For Izervay

Refiling Considered But Timing Unclear

 
• By Lisa Takagi
  
Astellas received CRL over its sNDA for Izervay. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from New Products